These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 33094713)
21. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627 [TBL] [Abstract][Full Text] [Related]
22. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729 [TBL] [Abstract][Full Text] [Related]
23. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. Jääskeläinen AJ; Kuivanen S; Kekäläinen E; Ahava MJ; Loginov R; Kallio-Kokko H; Vapalahti O; Jarva H; Kurkela S; Lappalainen M J Clin Virol; 2020 Aug; 129():104512. PubMed ID: 32563180 [TBL] [Abstract][Full Text] [Related]
24. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626 [TBL] [Abstract][Full Text] [Related]
25. A serological survey of SARS-CoV-2 in cat in Wuhan. Zhang Q; Zhang H; Gao J; Huang K; Yang Y; Hui X; He X; Li C; Gong W; Zhang Y; Zhao Y; Peng C; Gao X; Chen H; Zou Z; Shi ZL; Jin M Emerg Microbes Infect; 2020 Dec; 9(1):2013-2019. PubMed ID: 32867625 [TBL] [Abstract][Full Text] [Related]
26. National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance. Kumar MS; Bhatnagar T; Manickam P; Kumar VS; Rade K; Shah N; Kant S; Babu GR; Zodpey S; Girish Kumar CP; Vivian Thangaraj JW; Chatterjee P; Kanungo S; Pandey RM; Murhekar M; Singh SK; Sarkar S; Muliyi JP; Gangakhedkar RR; Reddy DCS Indian J Med Res; 2020 May; 151(5):419-423. PubMed ID: 32611913 [TBL] [Abstract][Full Text] [Related]
27. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. Marklund E; Leach S; Axelsson H; Nyström K; Norder H; Bemark M; Angeletti D; Lundgren A; Nilsson S; Andersson LM; Yilmaz A; Lindh M; Liljeqvist JÅ; Gisslén M PLoS One; 2020; 15(10):e0241104. PubMed ID: 33085715 [TBL] [Abstract][Full Text] [Related]
29. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384 [TBL] [Abstract][Full Text] [Related]
30. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. Bryan A; Pepper G; Wener MH; Fink SL; Morishima C; Chaudhary A; Jerome KR; Mathias PC; Greninger AL J Clin Microbiol; 2020 Jul; 58(8):. PubMed ID: 32381641 [TBL] [Abstract][Full Text] [Related]
31. Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia. Lynch SA; Subbarao K; Mahanty S; Barber BE; Roulis EV; van der Hoek L; McCarthy JS; Spann KM Viruses; 2021 Aug; 13(8):. PubMed ID: 34452482 [TBL] [Abstract][Full Text] [Related]